Abstract:

Objective To investigate the efficacy of regorafenib combined with microwave ablation and percutaneous transhepatic arterial chemoembolization (TACE) in the treatment of primary liver cancer. Method Seventy four patients with primary liver cancer admitted to the Tianjin Second People's Hospital from October 2023 to April 2024 were selected and divided into an observation group and a control group using the medical record number envelope drawing method, with 37 patients in each group. The control group received microwave ablation combined with TACE treatment, while the observation group received regorafenib combined with microwave ablation and TACE treatment. The short-term efficacy, tumor markers, biomarkers, liver function, and adverse reactions of the two groups were compared. Result The disease control rate of the observation group patients was signifi cantly higher than that of the control group, and the diff erence was signifi cant (P ＜ 0.05). After treatment, the levels of cytokeratin 19, alpha fetoprotein, carcinoembryonic antigen, as well as alanine aminotransferase and alanine aminotransferase in the observation group were significantly lower than those in the control group. The levels of fragile histidine triad, P16 protein, and albumin were higher than those in the control group, and the diff erences were signifi cant (P ＜ 0.05). Nine patients in the observation group experienced adverse reactions, while ten patients in the control group experienced adverse reactions. There was no signifi cant diff erence in the incidence of adverse reactions between the two groups of patients (P ＞ 0.05). Conclusion Primary liver cancer treated with regorafenib combined with microwave ablation and TACE can improve short-term effi cacy, alleviate liver function damage, and with high safety.

Key words: Regorafenib, Microwave ablation, Transcatheter arterial chemoembolization, Primary liver cancer